Keybank National Association OH Has $38 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Keybank National Association OH reduced its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 233,235 shares of the company's stock after selling 10,613 shares during the period. Keybank National Association OH owned about 0.05% of Zoetis worth $38,001,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Darwin Wealth Management LLC purchased a new position in shares of Zoetis in the third quarter worth approximately $31,000. First Personal Financial Services purchased a new position in shares of Zoetis in the third quarter worth approximately $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis in the third quarter worth approximately $33,000. Dunhill Financial LLC increased its position in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after acquiring an additional 75 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. UBS Group initiated coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price on the stock. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday. Finally, Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $215.90.

Remove Ads

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Zoetis Stock Performance

Shares of Zoetis stock traded up $3.09 on Friday, reaching $170.34. The stock had a trading volume of 3,296,788 shares, compared to its average volume of 3,274,650. The business's 50-day moving average price is $166.72 and its two-hundred day moving average price is $176.83. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The stock has a market cap of $76.28 billion, a P/E ratio of 31.14, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.